BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Wilson HR, Medjeral-Thomas NR, Gilmore AC, Trivedi P, Seyb K, Farzaneh-Far R, Gunnarsson I, Zickert A, Cairns TD, Lightstone L, Cook HT, Pickering MC. Glomerular membrane attack complex is not a reliable marker of ongoing C5 activation in lupus nephritis. Kidney Int 2019;95:655-65. [PMID: 30655025 DOI: 10.1016/j.kint.2018.09.027] [Cited by in Crossref: 18] [Cited by in F6Publishing: 15] [Article Influence: 6.0] [Reference Citation Analysis]
Number Citing Articles
1 Boudhabhay I, Poillerat V, Grunenwald A, Torset C, Leon J, Daugan MV, Lucibello F, El Karoui K, Ydee A, Chauvet S, Girardie P, Sacks S, Farrar CA, Garred P, Berthaud R, Le Quintrec M, Rabant M, de Lonlay P, Rambaud C, Gnemmi V, Fremeaux-Bacchi V, Frimat M, Roumenina LT. Complement activation is a crucial driver of acute kidney injury in rhabdomyolysis. Kidney Int 2021;99:581-97. [PMID: 33137339 DOI: 10.1016/j.kint.2020.09.033] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 5.0] [Reference Citation Analysis]
2 Koopman JJE, van Essen MF, Rennke HG, de Vries APJ, van Kooten C. Deposition of the Membrane Attack Complex in Healthy and Diseased Human Kidneys. Front Immunol 2020;11:599974. [PMID: 33643288 DOI: 10.3389/fimmu.2020.599974] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
3 Mastellos DC, Ricklin D, Lambris JD. Clinical promise of next-generation complement therapeutics. Nat Rev Drug Discov 2019;18:707-29. [PMID: 31324874 DOI: 10.1038/s41573-019-0031-6] [Cited by in Crossref: 99] [Cited by in F6Publishing: 93] [Article Influence: 33.0] [Reference Citation Analysis]
4 Fakhouri F, Schwotzer N, Golshayan D, Frémeaux-bacchi V. The rational use of complement inhibitors in kidney diseases. Kidney International Reports 2022. [DOI: 10.1016/j.ekir.2022.02.021] [Reference Citation Analysis]
5 Hong S, Healy H, Kassianos AJ. The Emerging Role of Renal Tubular Epithelial Cells in the Immunological Pathophysiology of Lupus Nephritis. Front Immunol 2020;11:578952. [PMID: 33072122 DOI: 10.3389/fimmu.2020.578952] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 2.5] [Reference Citation Analysis]
6 Davidson A, Aranow C, Mackay M. Lupus nephritis: challenges and progress. Curr Opin Rheumatol 2019;31:682-8. [PMID: 31389814 DOI: 10.1097/BOR.0000000000000642] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 2.5] [Reference Citation Analysis]
7 Medjeral-Thomas NR, Pickering MC, Cook HT. Complement and kidney disease, new insights. Curr Opin Nephrol Hypertens 2021;30:310-6. [PMID: 33767058 DOI: 10.1097/MNH.0000000000000705] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
8 Gilmore AC, Zhang Y, Cook HT, Lavin DP, Katti S, Wang Y, Johnson KK, Kim S, Pickering MC. Complement activity is regulated in C3 glomerulopathy by IgG-factor H fusion proteins with and without properdin targeting domains. Kidney Int 2021;99:396-404. [PMID: 33129896 DOI: 10.1016/j.kint.2020.09.028] [Reference Citation Analysis]
9 Nithagon P, Cortazar F, Shah SI, Weins A, Laliberte K, Jeyabalan A, Niles J, Zonozi R. Eculizumab and Complement Activation in Anti-glomerular Basement Membrane Disease. Kidney Int Rep 2021;6:2713-7. [PMID: 34622110 DOI: 10.1016/j.ekir.2021.07.001] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
10 Trachtman H, Laskowski J, Lee C, Renner B, Feemster A, Parikh S, Panzer SE, Zhong W, Cravedi P, Cantarelli C, Kulik L, You Z, Satchell S, Rovin B, Liu F, Kalled SL, Holers VM, Jalal D, Thurman JM. Natural antibody and complement activation characterize patients with idiopathic nephrotic syndrome. Am J Physiol Renal Physiol 2021;321:F505-16. [PMID: 34459222 DOI: 10.1152/ajprenal.00041.2021] [Reference Citation Analysis]
11 Bomback AS, Appel GB, Gipson DS, Hladunewich MA, Lafayette R, Nester CM, Parikh SV, Smith RJH, Trachtman H, Heeger PS, Ram S, Rovin BH, Ali S, Arceneaux N, Ashoor I, Bailey-Wickins L, Barratt J, Beck L, Cattran DC, Cravedi P, Erkan E, Fervenza F, Frazer-Abel AA, Fremeaux-Bacchi V, Fuller L, Gbadegesin R, Hogan JJ, Kiryluk K, le Quintrec-Donnette M, Licht C, Mahan JD, Pickering MC, Quigg R, Rheault M, Ronco P, Sarwal MM, Sethna C, Spino C, Stegall M, Vivarelli M, Feldman DL, Thurman JM. Improving Clinical Trials for Anticomplement Therapies in Complement-Mediated Glomerulopathies: Report of a Scientific Workshop Sponsored by the National Kidney Foundation. Am J Kidney Dis 2021:S0272-6386(21)00884-2. [PMID: 34571062 DOI: 10.1053/j.ajkd.2021.07.025] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
12 Cassol CA, Brodsky SV, Satoskar AA, Blissett AR, Cataland S, Nadasdy T. Eculizumab deposits in vessel walls in thrombotic microangiopathy. Kidney International 2019;96:761-8. [DOI: 10.1016/j.kint.2019.05.008] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 2.3] [Reference Citation Analysis]
13 Fakhouri F, Le Quintrec M, Frémeaux-Bacchi V. Practical management of C3 glomerulopathy and Ig-mediated MPGN: facts and uncertainties. Kidney Int 2020;98:1135-48. [PMID: 32622830 DOI: 10.1016/j.kint.2020.05.053] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 2.5] [Reference Citation Analysis]
14 Medjeral-Thomas NR, Moffitt H, Lomax-Browne HJ, Constantinou N, Cairns T, Cook HT, Pickering MC. Glomerular Complement Factor H-Related Protein 5 (FHR5) Is Highly Prevalent in C3 Glomerulopathy and Associated With Renal Impairment. Kidney Int Rep 2019;4:1387-400. [PMID: 31701048 DOI: 10.1016/j.ekir.2019.06.008] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 3.3] [Reference Citation Analysis]
15 Li NL, Birmingham DJ, Rovin BH. Expanding the Role of Complement Therapies: The Case for Lupus Nephritis. J Clin Med 2021;10:626. [PMID: 33562189 DOI: 10.3390/jcm10040626] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
16 Wang S, Wu M, Chiriboga L, Zeck B, Goilav B, Wang S, Jimenez AL, Putterman C, Schwartz D, Pullman J, Broder A, Belmont HM. Membrane attack complex (MAC) deposition in renal tubules is associated with interstitial fibrosis and tubular atrophy: a pilot study. Lupus Sci Med 2022;9:e000576. [PMID: 34996855 DOI: 10.1136/lupus-2021-000576] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
17 Ding Y, Yu X, Wu L, Tan Y, Qu Z, Yu F. The Spectrum of C4d Deposition in Renal Biopsies of Lupus Nephritis Patients. Front Immunol 2021;12:654652. [PMID: 34276649 DOI: 10.3389/fimmu.2021.654652] [Reference Citation Analysis]
18 Koopman JJE, Rennke HG, Leatherwood C, Speyer CB, D'Silva K, McMahon GM, Waikar SS, Costenbader KH. Renal deposits of complement factors as predictors of end-stage renal disease and death in patients with lupus nephritis. Rheumatology (Oxford) 2020;59:3751-8. [PMID: 32413140 DOI: 10.1093/rheumatology/keaa174] [Reference Citation Analysis]